Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Black Diamond Therapeutics (BDTX) EBITDA Margin (2025)

Black Diamond Therapeutics' EBITDA Margin history spans 1 years, with the latest figure at 80.71% for Q1 2025.

  • For Q1 2025, EBITDA Margin changed N/A year-over-year to 80.71%; the TTM value through Dec 2025 reached 32.06%, changed N/A, while the annual FY2025 figure was 32.06%, N/A changed from the prior year.
  • EBITDA Margin reached 80.71% in Q1 2025 per BDTX's latest filing.
  • In the past five years, EBITDA Margin ranged from a high of 80.71% in Q1 2025 to a low of 80.71% in Q1 2025.